ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2230

Serum Urate Levels in People with Gout on Dialysis – Are We Achieving Treatment Targets?

Estella Yeo1, Suetonia Palmer2, Peter T. Chapman3, Christopher Frampton4 and Lisa K. Stamp4, 1Canterbury District Health Board, Christchurch, New Zealand, 2University of Otago, Christchurch, Christchurch, New Zealand, 3Christchurch Hospital, Christchurch, New Zealand, 4University of Otago, Christchurch, New Zealand

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Allopurinol and gout, Kidney

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 23, 2018

Title: Metabolic and Crystal Arthropathies – Basic and Clinical Science Poster II

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: To explore the number of patients on haemodialysis (HD) or peritoneal dialysis (PD) with gout in Canterbury and to determine how many were receiving urate lowering therapy (ULT) and achieving target serum urate (SU).

Methods: Individuals with gout in Canterbury receiving dialysis for at least 90 days on 1st February 2017, 1st January 2016 and 1st January 2015 were identified. Pre-dialysis SU was recorded and SU levels for two days immediately post dialysis were estimated. These estimates were then used to estimate the percentage time serum urate was <0.36mmol/l using linear interpolation. Results were compared between those on ULT and not on ULT.

Results: 61/216 (28.8%) dialysis patients had gout.  Mean age was 61years (23- 84), 46/61 (75.4%) were male and 37/61 (60.7%) were European. 33/61 (54%) were receiving HD. 42/61 (68.9%) were receiving ULT, all allopurinol with a mean (SD) dose of 116.0 ± 66.9mg/d. A total of 936 pre-dialysis serum urate values were available from the 61 people with gout with a median (range) number of tests per participant of 15 (3-42). 46% of participants had a pre-dialysis SU <0.36mmol/l on less than 25% of occasions and 23% of participants were below target SU on 76-100% of occasions (Figure). There was no significant differences between those receiving HD and PD (median 35.3% vs. 20.0% p=0.39) and between those taking ULT and those not on ULT (median 34.5% vs. 27.8% p=0.55) in terms of % pre-dialysis urate below target (figure). The mean reduction in SU 24 and 48 hours post HD were 41% and 12% respectively as calculated from the previous study. The percentage time SU was below target two days post HD was only 41%, with no difference in those on or off ULT (43% vs 36%; p=0.55).

Conclusion: Gout is a common disease affecting 1/4 dialysis patients in Canterbury. The majority of our study patients were receiving ULT with allopurinol.  Dialysis alone is insufficient to lower SU and the use of ULT should be considered in those who remain above target SU using a treat to target SU approach.

Figure1: a) Percentage time at target in a) HD vs PD, b) on and off ULT and c) post HD


Disclosure: E. Yeo, None; S. Palmer, None; P. T. Chapman, None; C. Frampton, None; L. K. Stamp, Amgen Inc., 8.

To cite this abstract in AMA style:

Yeo E, Palmer S, Chapman PT, Frampton C, Stamp LK. Serum Urate Levels in People with Gout on Dialysis – Are We Achieving Treatment Targets? [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/serum-urate-levels-in-people-with-gout-on-dialysis-are-we-achieving-treatment-targets/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/serum-urate-levels-in-people-with-gout-on-dialysis-are-we-achieving-treatment-targets/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology